Navigation Links
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim's Olodaterol for Maintenance Treatment of COPD
Date:1/29/2013

RIDGEFIELD, Conn., Jan. 29, 2013 /PRNewswire/ -- Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) recommended that clinical data included in a new drug application (NDA) provide substantial and convincing evidence to support the approval of olodaterol as a once-daily maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. If approved by the FDA, it is anticipated that olodaterol will be marketed under the brand name Striverdi Respimat in the United States.

"We at Boehringer Ingelheim are pleased with the Advisory Committee's recommendation and look forward to continuing to work with the FDA as the Agency continues its review of the olodaterol NDA," said Tunde Otulana , MD, vice president, Clinical Development and Medical Affairs, Respiratory, Boehringer Ingelheim Pharmaceuticals, Inc.  "The positive vote from the Advisory Committee marks an important step towards making olodaterol available to the approximately 24 million patients with COPD in the United States."

The Committee also voted affirmatively that data showed the efficacy and safety of olodaterol supports approval of the 5 microgram dose. 

The Committee reviewed data from the Phase 3 olodaterol clinical trial program, including data from the 48-week and 6-week duration trials. These data are part of the NDA being reviewed to establish that olodaterol delivered once daily at the 5 microgram dose showed improvements in lung function, as measured by forced expiratory volume in one second (FEV1), in patients with moderate to very severe COPD compared to placebo and also active comparators.

The trials were conducted in a patient population represent
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
3. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
4. Generex Announces New Members of Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine
5. Generex Augments Antigen Express Scientific Advisory Board
6. IntelliCell Announces Dr. Arnold I. Caplan Joins Scientific Advisory Board
7. Generex Reports on Inaugural AE37 Breast Cancer Vaccine Scientific Advisory Board Meeting
8. Marken Announces Global Advisory Board
9. Obesity journal publishes new study on lorcaserin, a weight-loss medication recommended for approval by FDA advisory panel
10. Detroit Metro Convention & Visitors Bureau announces launch of Medical Meetings Initiative; recruits top leaders to Advisory Council
11. Oncos Therapeutics Announces Clinical Advisory Board for its Oncolytic Virus and Cancer Immunotherapy Development Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... September 16, 2014 Recently, BuyTopDress.com, one ... has unveiled its new collection of elegant graduation ... these brand new items are on sale on the ... from 23 to 63 percent off. , These ... and design. They are available in a lot of ...
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 Dr. ... the launch of ACLsurgeryLA.com , a specialty website ... injuries. As an avid sports lover and athlete, ... for treatment and recovery from injuries to maintain active, ... to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Lambda Solutions, a ... systems , is excited to welcome Stewart Rogers ... Harvey, Sales Executive at Lambda Solutions comments, “Product leadership will ... right candidate to do so. Learning and talent management is ... changes to help clinical learning and talent development in the ...
(Date:9/16/2014)... Birmingham, Alabama (PRWEB) September 16, 2014 *To ... Birmingham, AL, visit Achieve Clinical Research on the web ( ... For those who qualify:, There is ... required , Compensation may be provided for ... stands, pneumonia and influenza are the eighth leading cause of ...
Breaking Medicine News(10 mins):Health News:Cheap Graduation Dresses Now Provided Online At BuyTopDress.com 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3
... Sciton Inc., a manufacturer,of laser and ... announced the introduction of an additional fractional,device, ... features,-- significantly higher speed, and user-controlled, variable-depth ... results and excellent practice,economics., Up to ...
... Babies born,preterm were more than twice as likely ... a new analysis of nearly 7 million U.S.,live births ... and,Child Health Journal., Preterm birth, live birth before ... according to the March of Dimes. More than,a half ...
... that the frequency with which critically-ill patients developed,ventilator-associated ... medical center such as Mayo Clinic compared to ... National Healthcare Safety,Network (NHSN). This is good news ... generally strong across the U.S. in intensive care ...
... Dots beads led to a voluntary recall of the product ... that the potentially toxic chemical 1,4-butanediol (BD) had been used ... in the manufacture of the beads. , A new study, ... Irvine confirms these reports, finding that Aqua Dots contained no ...
... Inc. (OTC,Bulletin Board: SYMD) announced today that its Board ... The shareholder rights plan is,designed to ensure that shareholders ... an attempted takeover of the company and to protect ... plan,was not approved for adoption as a result of ...
... But, it may not be for every patient, one expert ... advanced prostate cancer that hasn,t spread beyond the gland should ... removed, a new long-term study says. , "What we are ... men who were treated with radiation and those who weren,t," ...
Cached Medicine News:Health News:Sciton Introduces ProFractional-XC(TM), High-Speed, Dual-Mode Fractional Laser 2Health News:Analysis of Millions of U.S. Births Shows Association Between Birth Defects and Preterm Birth 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 2Health News:Mayo Clinic Research Shows U.S. Intensive Care Units' Prevention of Pneumonia in Critically-ill Patients Generally Strong; Identifies Area of Improvement 3Health News:Study finds that recalled Aqua Dots did contain poisonous chemical 2Health News:SyntheMed, Inc. Adopts Shareholder Rights Plan 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 2Health News:Radiation Improves Survival for Advanced Prostate Cancer 3
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
Medicine Products: